ImmunoGenesis
Doylestown, US · Founded 2019 · Delaware corporation · 15 employees on LinkedIn · 5 known investors
Find your way into ImmunoGenesis
ImmunoGenesis is a clinical-stage immuno-oncology biopharmaceutical company developing immune therapies for immune-excluded tumors, which resist standard PD-1 blockade. Its lead candidate, IMGS-001, is a cytotoxic immune checkpoint inhibitor aimed at cancers such as colorectal, ovarian, and non–small cell lung cancer.
Founders & leadership
ImmunoGenesis was founded in 2019 by Michael A. Curran.
MA
Michael A. CurraninFounder
JB
Jennifer BarlowExecutive
CS
Clifford StocksExecutive
JB
James BarlowNamed on SEC filing
JB
Jeremy BartonNamed on SEC filing
FO
Federica O'BrienNamed on SEC filing
FP
Federica PericleNamed on SEC filing
Board
TK
Ted KoutouzisBoard director
RB
Robert B. SteinBoard director
TB
Thomas BartonBoard director
Investors · 5
Reported raises · per SEC filings
Form D private placements$50.2M disclosed across 2 rounds · 2024
▶$5.7MraisedJan 2025 · 2 investors · BiotechnologyRule 506(b)
▶$5.7MraisedJan 2025 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael A. CurranDirector
- Ted KoutouzisDirector
- Jennifer BarlowExecutive Officer, Director
- Robert B. SteinDirector
- Clifford StocksDirector
- Thomas BartonDirector
- Offering amount
- $25M
- Amount sold
- $5.7M
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$44.4MraisedApr 2024 · 88 investors · BiotechnologyRule 506(b)
▶$44.4MraisedApr 2024 · 88 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James BarlowExecutive Officer, Director
- Michael CurranDirector
- Jeremy BartonExecutive Officer
- Thomas BartonDirector
- Robert SteinDirector
- Ted KoutouzisDirector
- Federica O'BrienExecutive Officer
- Federica PericleExecutive Officer
- Clifford StocksDirector
- Offering amount
- $66.5M
- Amount sold
- $44.4M
- Finders' fees
- $243K
- Placement agents
- Spartan Capital Securities, LLC
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Immunome42 shared keywordsImmunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer. It also acquires targeted oncology assets and advances them through manufacturing and clinical development.
Immuneering36 shared keywordsImmuneering develops Deep Cyclic Inhibitors, a class of oncology medicines designed to pulse dosing faster than cancer's adaptive mechanisms to limit resistance and reduce side effects. The company targets more durable tumor control and improved tolerability for cancer patients.
Organogenesis31 shared keywordsOrganogenesis is a regenerative medicine company that develops and commercializes products for the advanced wound care and surgical biologics markets, supplying clinicians and their patients. Its product portfolio includes tissue-based therapies such as Apligraf for wound care.
Companies competing with ImmunoGenesis for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does ImmunoGenesis do?
- ImmunoGenesis is a clinical-stage immuno-oncology biopharmaceutical company developing immune therapies for immune-excluded tumors, which resist standard PD-1 blockade. Its lead candidate, IMGS-001, is a cytotoxic immune checkpoint inhibitor aimed at cancers such as colorectal, ovarian, and non–small cell lung cancer.
- Who founded ImmunoGenesis?
- ImmunoGenesis was founded by Michael A. Curran in 2019.
- Who are ImmunoGenesis's investors?
- ImmunoGenesis's investors include Adit Ventures Management, Llc, Angel Physicians Fund, BioAdvance, Service Provider Capital, Texas HALO Fund.
- How much funding has ImmunoGenesis raised?
- ImmunoGenesis has disclosed $50.2M raised across 2 rounds.
- Where is ImmunoGenesis headquartered?
- ImmunoGenesis is headquartered in Doylestown, US.